diff-quik solution sysmex reagent (Sysmex Corporation)
90
Structured Review
Sysmex Corporation
diff-quik solution sysmex reagent
Diff Quik Solution Sysmex Reagent, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/diff-quik+solution+sysmex+reagent/diff+quick+staining+sysmex/pm34971621-56-6-8
Average 90 stars, based on 1 article reviews
Diff Quik Solution Sysmex Reagent, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/diff-quik+solution+sysmex+reagent/diff+quick+staining+sysmex/pm34971621-56-6-8
Average 90 stars, based on 1 article reviews
diff-quik solution sysmex reagent - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Staining:Article Title: Effect of a peroxynitrite scavenger, a manganese-porphyrin compound on airway remodeling in a murine asthma. Article Snippet: Subsequently, cells were stained with Article Title: Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. Article Snippet: For differential cell counts, bronchoalveolar lavage cells were stained with Article Title: Pathogenic changes in group 2 innate lymphoid cells (ILC2s) in a steroid-insensitive asthma model of mice. Article Snippet: A certain population of asthma patients is resistant to steroid therapy, whereas the mechanisms remain unclear.. One of characteristic features of steroid-resistant asthma patients is severe airway eosinophilia based on type-2 inflammation.. Aims of this study were: 1) to develop a murine model of steroid-resistant asthma, 2) to elucidate that predominant cellular source of a type-2 cytokine, IL-5 was group 2 innate lymphoid cells (ILC2s), 3) to analyze pathogenic alteration of ILC2s in the severe asthma, and 4) to evaluate therapeutic potential of anti-IL-5 monoclonal antibody (mAb) on the steroid-resistant asthma. Article Title: Regulatory role of antigen-induced interleukin-10, produced by CD4(+) T cells, in airway neutrophilia in a murine model for asthma. Article Snippet: a Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan b Department of Pharmacology, Kobe Pharmaceutical University, Kobe 658-8558, Japan c Department of Pathological Biochemistry, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan d Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA Diff-Quik:Article Title: Effect of a peroxynitrite scavenger, a manganese-porphyrin compound on airway remodeling in a murine asthma. Article Snippet: Subsequently, cells were stained with Article Title: Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. Article Snippet: For differential cell counts, bronchoalveolar lavage cells were stained with Article Title: Pathogenic changes in group 2 innate lymphoid cells (ILC2s) in a steroid-insensitive asthma model of mice. Article Snippet: A certain population of asthma patients is resistant to steroid therapy, whereas the mechanisms remain unclear.. One of characteristic features of steroid-resistant asthma patients is severe airway eosinophilia based on type-2 inflammation.. Aims of this study were: 1) to develop a murine model of steroid-resistant asthma, 2) to elucidate that predominant cellular source of a type-2 cytokine, IL-5 was group 2 innate lymphoid cells (ILC2s), 3) to analyze pathogenic alteration of ILC2s in the severe asthma, and 4) to evaluate therapeutic potential of anti-IL-5 monoclonal antibody (mAb) on the steroid-resistant asthma. Article Title: Regulatory role of antigen-induced interleukin-10, produced by CD4(+) T cells, in airway neutrophilia in a murine model for asthma. Article Snippet: a Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan b Department of Pharmacology, Kobe Pharmaceutical University, Kobe 658-8558, Japan c Department of Pathological Biochemistry, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan d Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA Light Microscopy:Article Title: Effect of a peroxynitrite scavenger, a manganese-porphyrin compound on airway remodeling in a murine asthma. Article Snippet: Subsequently, cells were stained with Article Title: Complement C3a-induced IL-17 plays a critical role in an IgE-mediated late-phase asthmatic response and airway hyperresponsiveness via neutrophilic inflammation in mice. Article Snippet: For differential cell counts, bronchoalveolar lavage cells were stained with Article Title: Pathogenic changes in group 2 innate lymphoid cells (ILC2s) in a steroid-insensitive asthma model of mice. Article Snippet: A certain population of asthma patients is resistant to steroid therapy, whereas the mechanisms remain unclear.. One of characteristic features of steroid-resistant asthma patients is severe airway eosinophilia based on type-2 inflammation.. Aims of this study were: 1) to develop a murine model of steroid-resistant asthma, 2) to elucidate that predominant cellular source of a type-2 cytokine, IL-5 was group 2 innate lymphoid cells (ILC2s), 3) to analyze pathogenic alteration of ILC2s in the severe asthma, and 4) to evaluate therapeutic potential of anti-IL-5 monoclonal antibody (mAb) on the steroid-resistant asthma. Article Title: Regulatory role of antigen-induced interleukin-10, produced by CD4(+) T cells, in airway neutrophilia in a murine model for asthma. Article Snippet: a Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan b Department of Pharmacology, Kobe Pharmaceutical University, Kobe 658-8558, Japan c Department of Pathological Biochemistry, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan d Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294-2170, USA |